Schering Results Miss Targets
251914
The disappointing resuslts sent shares down more than 10 percent amid concerns about its flagship cholesterol drugs.
268759
The larger pharmaceutical drops out of daclizumab development.
434277
The market might overlook the drug maker's promising programs.
205867
German drug maker Schering, recently acquired by pharmaceuticals and chemicals giant Bayer, has said that it was teaming up with British drug giant AstraZeneca to develop a new treatment against breast cancer.
520589
Investors are discouraged after it releases the latest data for its top drug.
498388
German drug maker Schering AG (SCHG.DE: Quote , Profile , Research ) was boosted on Thursday as the U.S. Food and Drug Administration granted its Bonefos treatment "priority review" for preventing bone tumours ...
730824
Charges hurt the quarterly results of Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but the drugmakers' shares rose as J&J's earnings beat Wall Street forecasts and Merck sales edged higher despite the withdrawal of its best-selling Vioxx arthritis drug.
20326
When a great launch of a good drug is not enough.
471279
The Thursday night rejection of Proctor &amp; Gamble&#39;s (PG:NYSE - news - research) female testosterone sex-drive patch Intrinsa by a Food and Drug Administration advisory panel will almost certainly delay efforts by BioSante to develop its own product, a
161495
Progress on its lead drug remains stalled.
138928
Misaligned incentives are leading two potentially life-saving drugs for treating lymphoma to go underused.
550692
NEW YORK - Today at the UBS Global Life Sciences Conference, AtheroGenics was met with pointed skepticism over trial results for its drug, AGI-1067.
370237
Schering-Plough's positive study results send shares of Vertex down.
185290
Not every drug invented in the laboratory is worth developing into a marketable product.
217275
In the cold, calculating world of Wall Street, that&#39;s how the unfolding drama of new test results on old drugs is playing out, as analysts see bright spots for Pfizer (PFE:NYSE - news - research) amid other drugs&#39; woes.
63189
Bayer forged an alliance for its struggling pharmaceuticals business with American drug manufacturer Schering-Plough yesterday, cutting costs and marking another step in the German company&#39;s transformation.
482214
Chiron, the biotechnology company that left the US short of half its normal supply of flu vaccine this winter after contamination fears at its Speke factory in Liverpool, has